Last reviewed · How we verify
late leukostim
Late leukostim stimulates the proliferation of hematopoietic progenitor cells.
Late leukostim stimulates the proliferation of hematopoietic progenitor cells. Used for Treatment of severe chronic neutropenia.
At a glance
| Generic name | late leukostim |
|---|---|
| Also known as | 5leuko |
| Sponsor | Hyuk moon Kim |
| Drug class | Growth factor |
| Target | G-CSF receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Late leukostim works by stimulating the proliferation of hematopoietic progenitor cells, which are essential for the production of blood cells. This is achieved through the activation of specific signaling pathways that promote cell growth and differentiation.
Approved indications
- Treatment of severe chronic neutropenia
Common side effects
- Bone pain
- Headache
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- late leukostim CI brief — competitive landscape report
- late leukostim updates RSS · CI watch RSS
- Hyuk moon Kim portfolio CI